1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Disgruntled Ramius offers $4.00 per share for rest of Cypress Bioscience

 
• By Peter Mansell

A disgruntled major shareholder has launched a $4.00 per share takeover bid for Cypress Bioscience, the US company best known for its fibromyalgia treatment Savella (milnacipran HCl).

A disgruntled major shareholder has launched a $4.00 per share takeover bid for Cypress Bioscience, the US company best known for its fibromyalgia treatment Savella (milnacipran HCl).

Ramius Value and Opportunity Advisers, a subsidiary of investment management business Ramius LLC, has sent a letter to the Cyprus board outlining the unsolicited cash offer and castigating the company's management for a record of "ill-conceived"

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapeutic Category

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.